JP2022547505A5 - - Google Patents

Info

Publication number
JP2022547505A5
JP2022547505A5 JP2022514833A JP2022514833A JP2022547505A5 JP 2022547505 A5 JP2022547505 A5 JP 2022547505A5 JP 2022514833 A JP2022514833 A JP 2022514833A JP 2022514833 A JP2022514833 A JP 2022514833A JP 2022547505 A5 JP2022547505 A5 JP 2022547505A5
Authority
JP
Japan
Application number
JP2022514833A
Other languages
Japanese (ja)
Other versions
JP7753197B2 (ja
JPWO2021044379A5 (https=
JP2022547505A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/058281 external-priority patent/WO2021044379A1/en
Publication of JP2022547505A publication Critical patent/JP2022547505A/ja
Publication of JP2022547505A5 publication Critical patent/JP2022547505A5/ja
Publication of JPWO2021044379A5 publication Critical patent/JPWO2021044379A5/ja
Priority to JP2025117434A priority Critical patent/JP2025170191A/ja
Application granted granted Critical
Publication of JP7753197B2 publication Critical patent/JP7753197B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022514833A 2019-09-05 2020-09-04 ユニバーサルドナー細胞 Active JP7753197B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025117434A JP2025170191A (ja) 2019-09-05 2025-07-11 ユニバーサルドナー細胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962896473P 2019-09-05 2019-09-05
US62/896,473 2019-09-05
US202062979771P 2020-02-21 2020-02-21
US62/979,771 2020-02-21
PCT/IB2020/058281 WO2021044379A1 (en) 2019-09-05 2020-09-04 Universal donor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025117434A Division JP2025170191A (ja) 2019-09-05 2025-07-11 ユニバーサルドナー細胞

Publications (4)

Publication Number Publication Date
JP2022547505A JP2022547505A (ja) 2022-11-14
JP2022547505A5 true JP2022547505A5 (https=) 2023-09-11
JPWO2021044379A5 JPWO2021044379A5 (https=) 2023-09-11
JP7753197B2 JP7753197B2 (ja) 2025-10-14

Family

ID=72473593

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022514833A Active JP7753197B2 (ja) 2019-09-05 2020-09-04 ユニバーサルドナー細胞
JP2025117434A Pending JP2025170191A (ja) 2019-09-05 2025-07-11 ユニバーサルドナー細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025117434A Pending JP2025170191A (ja) 2019-09-05 2025-07-11 ユニバーサルドナー細胞

Country Status (13)

Country Link
US (5) US11104918B2 (https=)
EP (1) EP4025690A1 (https=)
JP (2) JP7753197B2 (https=)
KR (1) KR20220052370A (https=)
CN (1) CN114375300A (https=)
AU (1) AU2020341186A1 (https=)
BR (1) BR112022004026A2 (https=)
CA (1) CA3150235A1 (https=)
CO (1) CO2022002586A2 (https=)
IL (1) IL291044A (https=)
MX (1) MX2022002783A (https=)
PH (1) PH12022550543A1 (https=)
WO (1) WO2021044379A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
KR20220058579A (ko) 2019-09-05 2022-05-09 크리스퍼 테라퓨틱스 아게 보편적 공여자 세포
US11104918B2 (en) 2019-09-05 2021-08-31 Crispr Therapeutics Ag Universal donor cells
KR20230146007A (ko) 2020-12-31 2023-10-18 크리스퍼 테라퓨틱스 아게 범용 공여자 세포
AU2022283291A1 (en) * 2021-05-27 2023-11-02 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
WO2023183313A1 (en) * 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
CN116732099B (zh) * 2023-08-07 2023-11-24 北赛泓升(北京)生物科技有限公司 一种干细胞多重CRISPR/Cas基因组编辑方法
WO2025202874A1 (en) 2024-03-25 2025-10-02 Crispr Therapeutics Ag Genetically modified cells expressing glp-1 receptor agonist
WO2026069163A1 (en) 2024-09-25 2026-04-02 Crispr Therapeutics Ag Differentiation method for producing immature beta cells

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US20060222633A1 (en) 2000-05-11 2006-10-05 Yale University Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host
WO2003014313A2 (en) 2001-08-06 2003-02-20 Bresagen, Ltd. Alternative compositions and methods for the culture of stem cells
US7541185B2 (en) 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
CN103898047B (zh) 2003-12-23 2020-03-03 维亚希特公司 定形内胚层
WO2007059007A2 (en) 2005-11-14 2007-05-24 Cythera, Inc. Markers of definitive endoderm
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
EP1791952A4 (en) 2004-08-13 2008-06-11 Univ Georgia Res Found COMPOSITIONS AND METHODS OF SELF-RENEWAL AND DIFFERENTIATION IN HUMAN EMBRYONAL STEM CELLS
EP1856526A4 (en) 2005-01-20 2008-11-12 Univ Rochester THIOREDOXIN-INTERACTING PROTEIN (TXNIP) AS REGULATOR OF VASCULAR FUNCTION
AU2006305879B2 (en) 2005-10-27 2012-05-10 Viacyte, Inc. PDX1-expressing dorsal and ventral foregut endoderm
KR20080109775A (ko) 2006-02-23 2008-12-17 노보셀, 인크 분화가능한 세포를 배양하는데 유용한 조성물 및 방법
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
EP1999253B1 (en) 2006-03-02 2019-05-22 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
WO2007139929A2 (en) 2006-05-25 2007-12-06 The Burnham Institute For Medical Research Methods for culture and production of single cell populations of human embryonic stem cells
CA3114827C (en) 2007-07-31 2023-09-05 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic endocrine
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8623650B2 (en) 2007-10-19 2014-01-07 Viacyte, Inc. Methods and compositions for feeder-free pluripotent stem cell media containing human serum
EP2229434B1 (en) 2007-11-27 2011-09-07 Lifescan, Inc. Differentiation of human embryonic stem cells
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
US7939322B2 (en) 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm
US20120058105A1 (en) 2008-06-27 2012-03-08 Martin Kean Chong Ng Method of treatment of vascular complications
PL2346988T3 (pl) 2008-10-31 2017-10-31 Janssen Biotech Inc Różnicowanie ludzkich zarodkowych komórek macierzystych do linii endokrynnej trzustki
MX349178B (es) 2008-10-31 2017-07-17 Centocor Ortho Biotech Inc Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático.
US8895300B2 (en) 2008-11-04 2014-11-25 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
US8008075B2 (en) 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
AU2009313870B2 (en) 2008-11-14 2013-07-11 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US20100272710A1 (en) * 2009-03-26 2010-10-28 Abdelhadi Rebbaa Compositions and methods for treating and preventing aging-associated diseases
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US20100272695A1 (en) 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
US8685726B2 (en) 2009-04-27 2014-04-01 Viacyte, Inc. Small molecules supporting pluripotent cell growth and methods thereof
EP2456859A4 (en) 2009-07-20 2015-03-18 Janssen Biotech Inc DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS
SG177483A1 (en) 2009-07-20 2012-02-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
SG181687A1 (en) 2009-12-23 2012-07-30 Centocor Ortho Biotech Inc Differentiation of human embryonic stem cells
CA2784425A1 (en) 2009-12-23 2011-06-30 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
EP2611907B1 (en) 2010-08-31 2016-05-04 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
ES2658146T3 (es) 2010-08-31 2018-03-08 Janssen Biotech, Inc. Diferenciación de células madre embrionarias humanas
AU2010365057B2 (en) 2010-12-08 2016-12-22 Viacyte, Inc. Agents and methods for inhibiting human pluripotent stem cell growth
WO2012145384A1 (en) 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
KR102203056B1 (ko) 2011-12-22 2021-01-14 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
ES2615346T3 (es) * 2012-04-25 2017-06-06 Deutsches Krebsforschungszentrum Inhibidores de la proteína que interacciona con tiorredoxina (TXNIP) para terapia
JP6450674B2 (ja) 2012-05-07 2019-01-09 ヤンセン バイオテツク,インコーポレーテツド ヒト胚性幹細胞の膵臓の内胚葉への分化
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
AU2013271581B2 (en) 2012-06-08 2018-08-09 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
EP2861723A4 (en) 2012-06-14 2016-01-20 Janssen Biotech Inc DIFFERENTIATION OF HUMAN EMBRYONAL STEM CELLS IN ENDOCRINE PANCREAS CELLS
CN105121648B (zh) 2012-12-12 2021-05-07 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
JP6557147B2 (ja) 2012-12-31 2019-08-07 ヤンセン バイオテツク,インコーポレーテツド Hb9調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化
RU2687379C2 (ru) 2012-12-31 2019-05-13 Янссен Байотек, Инк. Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
BR112015015770A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US9101597B2 (en) * 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
SG11201510177WA (en) 2013-06-11 2016-01-28 Harvard College SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
KR20140144964A (ko) 2013-06-12 2014-12-22 한국생명공학연구원 티오레독신-결합 단백질을 유효성분으로 포함하는 약학적 조성물 및 이의 용도
KR20250012194A (ko) * 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
KR20160079072A (ko) 2013-11-01 2016-07-05 얀센 바이오테크 인코포레이티드 췌장 내분비 세포로의 분화를 위한 인간 만능 줄기세포의 현탁 및 클러스터링
MX373460B (es) * 2014-03-11 2020-04-07 Cellectis Metodo para generar celulas t compatibles para el trasplante alogenico.
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
AU2015363008B2 (en) 2014-12-19 2021-12-09 Janssen Biotech, Inc. Suspension culturing of pluripotent stem cells
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
JP6928604B2 (ja) 2015-11-04 2021-09-01 フェイト セラピューティクス,インコーポレイテッド 万能性細胞のゲノム改変
CN110312799A (zh) 2016-08-17 2019-10-08 博德研究所 新型crispr酶和系统
US9982267B2 (en) 2016-10-12 2018-05-29 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
DK3537986T3 (da) 2016-11-10 2025-07-21 Viacyte Inc Pdx1 pankreatiske endodermceller i celleleveringsanordning
CN110177869A (zh) 2017-01-13 2019-08-27 加利福尼亚大学董事会 免疫改造的多能细胞
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
KR20200075851A (ko) 2017-10-19 2020-06-26 셀렉티스 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
US20190223416A1 (en) 2018-01-23 2019-07-25 Cotyledon, LLC Canine genome editing
EP3754018A4 (en) 2018-02-16 2021-11-24 Kyoto University LOW ANTIGENIC CELL PRODUCTION PROCESS
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
KR20220058579A (ko) 2019-09-05 2022-05-09 크리스퍼 테라퓨틱스 아게 보편적 공여자 세포
US11104918B2 (en) * 2019-09-05 2021-08-31 Crispr Therapeutics Ag Universal donor cells

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
JP2022547505A5 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016176A2 (https=)